|
| 1 |
|
Conditions listed in this trial |
|
|
Leukemia |
|
|
Lymphoma |
|
| 2 |
|
Additional conditions recognized in this trial |
|
|
Lymphoma, Non-Hodgkin |
|
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
|
| 3 |
|
More general conditions related to this trial |
|
|
Immune System Diseases |
|
|
Immunoproliferative Disorders |
|
|
Leukemia, Lymphoid |
|
|
Lymphatic Diseases |
|
|
Lymphoproliferative Disorders |
|
|
Neoplasms |
|
|
Neoplasms by Histologic Type |
|
| 4 |
|
Interventions listed in this trial |
|
|
cyclophosphamide |
|
|
cytarabine |
|
|
dexamethasone |
|
|
doxorubicin hydrochloride |
|
|
etoposide |
|
|
ifosfamide |
|
|
leucovorin calcium |
|
|
mesna |
|
|
methotrexate |
|
|
prednisone |
|
|
therapeutic hydrocortisone |
|
|
vincristine sulfate |
|
|
low-LET cobalt-60 gamma ray therapy |
|
|
low-LET photon therapy |
|
| 5 |
|
Additional drug interventions recognized in this trial |
|
|
Cortisol succinate |
|
|
Doxorubicin |
|
|
Hydrocortisone |
|
|
Hydrocortisone acetate |
|
|
Leucovorin |
|
|
Vincristine |
|
| 6 |
|
More general drug interventions related to this trial |
|
|
Abortifacient Agents |
|
|
Abortifacient Agents, Nonsteroidal |
|
|
Alkylating Agents |
|
|
Anti-Infective Agents |
|
|
Anti-Inflammatory Agents |
|
|
Antibiotics, Antineoplastic |
|
|
Antiemetics |
|
|
Antimetabolites |
|
|
Antimetabolites, Antineoplastic |
|
|
Antimitotic Agents |
|
|
Antineoplastic Agents |
|
|
Antineoplastic Agents, Alkylating |
|
|
Antineoplastic Agents, Hormonal |
|
|
Antineoplastic Agents, Phytogenic |
|
|
Antirheumatic Agents |
|
|
Antiviral Agents |
|
|
Autonomic Agents |
|
|
Central Nervous System Agents |
|
|
Dermatologic Agents |
|
|
Enzyme Inhibitors |
|
|
Folic Acid Antagonists |
|
|
Gastrointestinal Agents |
|
|
Glucocorticoids |
|
|
Growth Substances |
|
|
Hormones |
|
|
Hormones, Hormone Substitutes, and Hormone Antagonists |
|
|
Immunologic Factors |
|
|
Immunosuppressive Agents |
|
|
Micronutrients |
|
|
Mitosis Modulators |
|
|
Molecular Mechanisms of Pharmacological Action |
|
|
Myeloablative Agonists |
|
|
Nucleic Acid Synthesis Inhibitors |
|
|
Peripheral Nervous System Agents |
|
|
Pharmacologic Actions |
|
|
Physiological Effects of Drugs |
|
|
Reproductive Control Agents |
|
|
Therapeutic Uses |
|
|
Tubulin Modulators |
|
|
Vitamin B Complex |
|
|
Vitamins |
|
| 7 |
|
Sponsors listed in this trial |
|
|
Cancer and Leukemia Group B |
|
|
National Cancer Institute (NCI) |
